At a glance
- Originator Merck & Co
- Class Antithrombotics; Pyrrolidines
- Mechanism of Action Thrombin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 03 Aug 1998 New profile
- 03 Aug 1998 Preclinical development for Thrombosis in USA (Unknown route)